Next Article in Journal
The Transcriptional Repressor, MtrR, of the mtrCDE Efflux Pump Operon of Neisseria gonorrhoeae Can Also Serve as an Activator of “off Target” Gene (glnE) Expression
Previous Article in Journal
Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review
Article Menu

Export Article

Open AccessArticle
Antibiotics 2015, 4(2), 179-187; doi:10.3390/antibiotics4020179

Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library

1
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
2
Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
3
Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China
4
Department of Clinical Microbiology Lab, Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Christopher C. Butler
Received: 5 April 2015 / Revised: 5 May 2015 / Accepted: 7 May 2015 / Published: 12 May 2015
View Full-Text   |   Download PDF [834 KB, uploaded 12 May 2015]   |  

Abstract

Uropathogenic E. coli is a major cause of urinary tract infections (UTIs), but current antibiotics do not always effectively clear the persistent infection. To identify drugs that eliminate uropathogenic E. coli persisters, we screened a clinical drug library consisting of 1524 compounds using high throughput drug exposure assay in 96-well plates. Bacterial survival was assessed by growth on LB plates. We identified 14 drug candidates (tosufloxacin, colistin, sparfloxacin, moxifloxacin and gatifloxacin, enrofloxacin and sarafloxacin, octodrine, clofoctol, dibekacin, cephalosporin C, pazufloxacin, streptomycin and neomycin), which had high anti-persister activity. Among them, tosufloxacin and colistin had the highest anti-persister activity and could completely eradicate E. coli persisters in 3 days in vitro while the current UTI antibiotics failed to do so. Our findings may have implications for the development of a more effective treatment for UTIs. View Full-Text
Keywords: Escherichia coli; persisters; anti-persister activity; clinical drug library; urinary tract infection Escherichia coli; persisters; anti-persister activity; clinical drug library; urinary tract infection
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Niu, H.; Cui, P.; Shi, W.; Zhang, S.; Feng, J.; Wang, Y.; Sullivan, D.; Zhang, W.; Zhu, B.; Zhang, Y. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics 2015, 4, 179-187.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top